Skip to main content

Trinity College Dublin, The University of Dublin

Menu Search


Trinity College Dublin By using this website you consent to the use of cookies in accordance with the Trinity cookie policy. For more information on cookies see our cookie policy.

      
Profile Photo

Dr. Beatrice Nolan

Clinical Senior Lecturer (Paediatrics)
      
Profile Photo

Dr. Beatrice Nolan

Clinical Senior Lecturer (Paediatrics)

 emnolan@tcd.ie

 


  Blood transfusion   Clinical research, trials   Coagulation biochemistry and disorders   Drug development and evaluation   Haemotology   Human blood transfusion, risk managment   Inflammation and coagulation syndromes   Medical Sciences, Research   Medicine   Thrombosis and haemostasis
Project Title
 An Open-Label, Multicenter Evaluation of the Long-Term Safety and Efficacy of Recombinant Human Coagulation Factor VIII Fusion Protein (rFVIIIFc) in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia A
From
To
Summary
Funding Agency
Bioverative Therapeutics Inc
Project Type
Phase 3 interventional clinical trial
Project Title
 An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Previously Untreated Males With Severe Hemophilia A
From
To
Summary
The primary objective of the study was to evaluate the safety of rFVIIIFc (BIIB031) in previously untreated participants (PUPs) with severe hemophilia A. The secondary objectives were to evaluate the efficacy of rFVIIIFc in the prevention and treatment of bleeding episodes in PUPs, to evaluate rFVIIIFc consumption for the prevention and treatment of bleeding episodes in PUPs, and to describe experience with the use of rFVIIIFc for immune tolerance induction (ITI) in participants with inhibitors.
Funding Agency
Bioverativ, a Sanofi company
Project Type
Phase 3 interventional clinical trial
Project Title
 A Non-Controlled, Open-Label, Multicenter, Study of Immune Tolerance Induction Performed With rFVIIIFc Within a Timeframe of 60 Weeks in Severe Haemophilia A Patients With Inhibitors Who Have Failed Previous Immune Tolerance Induction Therapies
From
To
Summary
The primary purpose of this study is to describe the outcome of Immune Tolerance Induction (ITI) treatment performed with rFVIIIFc within a timeframe of 60 weeks in patients with haemophilia A who have failed previous attempts at tolerization.
Funding Agency
Swedish Orphan Biovitrum
Project Type
Phase 3 interventional clinical trial
Project Title
 A Chart Review Study of Patients With Haemophilia A With Inhibitors Treated With rFVIIIFc (Elocta®) for Immune Tolerance Induction
From
To
Summary
Funding Agency
Swedish Orphan Biovitrum
Project Type
A multicenter, international, non- interventional, retrospective and prospective clinical trial
Project Title
 A Multicenter Phase III Uncontrolled Open-label Trial to Evaluate Safety and Efficacy of BAY81-8973 in Children With Severe Hemophilia A Under Prophylaxis Therapy
From
To
Summary
The primary objective was to evaluate the safety and efficacy of the treatment with BAY81-8973 for prophylaxis and treatment of breakthrough bleeds in children with severe hemophilia A.
Funding Agency
Bayer
Project Type
Phase 3 interventional clinical trial

Page 1 of 4
Details Date From Date To
Member of Royal Academy of Medicine in Ireland
Member of Royal Society of Medicine
Member of European Association of Haemophilia and Allied Disorders
International Society of Thrombosis and Hemostasis 1999
Member of European Haematology Association
Member of HPRA Panel of External Clinical Experts 2022
Irene E. Regan ,Dermot Cox ,Sean T. Kelleher ,Beatrice Nolan ,Kathryn Shaw (,Owen P. Smith ,Colin J. McMahon, Towards a greater understanding of reduced response to aspirin in children with congenital heart disease post-cardiac surgery using immature platelet fraction, Thrombosis Research, 2024, Journal Article, PUBLISHED  DOI  URL
Kenet G, Nolan B, Zülfikar OB, Antmen B, Kampmann P, Matsushita T, You CW, Vilchevska K, Bagot CN, Sharif A, Peyvandi F, Young G, Negrier CG, Chi J, Kittner B, Sussebach C, Shammas F, Mei B, Andersson SR, Kavakli K., Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis (ATLAS-PPX). , Blood, 2024, pblood.2023021864 , Journal Article, PUBLISHED  DOI  URL
van der Zwet, Konrad, de Kovel, Marloes, Motwani, Jayashree, van Geet, Chris, Nolan, Beatrice, Glosli, Heidi, Escuriola Ettingshausen, Carmen, Königs, Christoph, Kenet, Gili, Fischer, Kathelijn, , , Bleeding control improves after switching to emicizumab: Real"world experience of 177 children in the PedNet registry, Haemophilia, 30, (3), 2024, p685-692 , Journal Article, PUBLISHED  DOI
Chowdary, Pratima, Ofori-Asenso, Richard, Nissen, Francis, Grazzi, Enrico F., Aizenas, Martynas, Moreno, Katya, Burke, Tom, Nolan, Beatrice, O'Hara, Jamie, Khair, Kate, Disease Burden, Clinical Outcomes, and Quality of Life in People with Hemophilia A without Inhibitors in Europe: Analyses from CHESS II/CHESS PAEDs, TH Open, 08, (02), 2024, pe181-e193 , Journal Article, PUBLISHED  DOI
Nolan, Beatrice, Recht, Michael, Rendo, Pablo, Falk, Aletta, Foster, Meredith, Casiano, Sandra, Rauch, Antoine, Shapiro, Amy, Prophylaxis with recombinant factor IX Fc fusion protein reduces the risk of bleeding and delays time to first spontaneous bleed event in previously untreated patients with haemophilia B: A post hoc analysis of the PUPs B"LONG study, European Journal of Haematology, 2024, Journal Article, PUBLISHED  DOI
de Kovel, Marloes S., Escuriola-Ettingshausen, Carmen, Königs, Christoph, Ranta, Susanna, Fischer, Kathelijn, Alvarèz Román, M.T., Benitez Hidalgo, O., Blatny, J., Bührlen, M., Carvalho, M., Chambost, H., Rosa Cid, A., Oudot, C., Escuriola-Ettingshausen, C., Fischer, K., Van Geet, C., Glosli, H., Gretenkort Andersson, N., Ljung, R., Königs, C., Koskenvuo, M., Male, C., Stamm Mikkelsen, T., Molinari, A., Motwani, J., Nolan, B., d"Oiron, R., Oldenburg, J., Olivieri, M., Pergantou, H., Pinto, F., Ranta, S., Kartal-Kaess, M., Zápotocká, E., Kenet, G., Carcao, M., Rivard, G., Bleeding phenotype according to factor level in 825 children with nonsevere hemophilia: data from the PedNet cohort, Journal of Thrombosis and Haemostasis, 2024, Journal Article, PUBLISHED  DOI
Khan A.Z., Kavanagh M., Kelly I., Ferry C., Ahmed S., Nolan B., Intramuscular vaccination in children with haemophilia: A single centre experience and review of the literature, Haemophilia, 2023, Journal Article, PUBLISHED  DOI
Shapiro, Amy D., Kulkarni, Roshni Daniel, Ragni, Margaret V, Chambost, Herve, Mahlangu, Johnny N, Oldenburg, Johannes, Nolan, Beatrice, Ozelo, Margareth C, Foster, Meredith C, Willemze, Annemieke, Barnowski, Chris, Jain, Nisha, Winding, Bent, Dumont, Jennifer, Lethagen, Stefan, Barnes, Chris, Pasi, K John, Post hoc longitudinal assessment of efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B, Blood Advances, 2023, Journal Article, PUBLISHED  DOI
Eliwan HO, Watson WRG, Melo AM, Kelly LA, Omer M, Jafar A, O'Hare FM, Downey P, Mooney EE, O'Neill A, Blanco A, Regan I, Philbin B, O'Rourke M, Nolan B, Smith O, Molloy EJ., Selective modulation of monocyte and neutrophil responses with activated protein C in preterm infants., J Matern Fetal Neonatal Med, 36, (1), 2023, p2183467 , Journal Article, PUBLISHED  DOI
Young G., Lenting P.J., Croteau S.E., Nolan B., Srivastava A., Antithrombin lowering in hemophilia: a closer look at fitusiran, Research and Practice in Thrombosis and Haemostasis, 7, (4), 2023, Journal Article, PUBLISHED  DOI
  

Page 1 of 11
Beatrice Nolan, Inhibitors in Haemophilia A, The Third International Medical Conference on Hemophilia, Thalassaemia and Sickle Cell Disease, Amman, Jordan, 2022, Jordanian Ministry of Health, Jordanian Thalassaemia and Hemophilia Society, World Federation of Hemophilia, Thalassemia International Federation, Invited Talk, PRESENTED
Beatrice Nolan, Prophylaxis for children with haemophilia, The Second International Medical Conference on Hemophilia, Thalassaemia and Sickle Cell Disease, Amman, Jordan, 26 -27 September , 2019, Jordanian Ministry of Health, Jordanian Thalassaemia and Hemophilia Society, World Federation of Hemophilia, Thalassemia International Federation, Invited Talk, PRESENTED
Beatrice Nolan, Hemophilia A (Case Based Presentation) ISTH Academy. Nolan B. 07/19/18; 223593 Topic: Hemophilia - Clinical, Dublin, 19/07/2018, 2018, Invited Talk, PRESENTED
Beatrice Nolan, ITI in era of Emicizumab, 64th Annual Meeting of Scientific and Standardization Committee of ISTH, Dublin, 20 July 2018, 2018, ISTH SSC, Invited Talk, PRESENTED
Kolawole, O., Kelly, B.D., Abstracts: Psychiatry, Hospital Doctor of Ireland, 17, (8), 2011, 48 - 49, Miscellaneous, PUBLISHED